N-phenylacridin-9-amine derivative having anticancer activity on the human adenocarcinoma (colon and rectal)\r\ntumor (HT-29) cell line, human nasopharyngeal carcinoma (HONE-1) cell line, human brain tumor (DBTRG) cell line, gastric\r\ncarcinoma TSGH, hepatoma liver hepa-G2, mouth carcinoma KB, lung adenocarcinoma H460, breast adenocarcinoma MX-1 and\r\nMCF-7 cell line and it�s significant cytotoxic activity against human leukemic HL-60 cell growth. N-phenylacridin-9-amine\r\nderivative exhibit both in-vivo as well as in-vitro potent antitumor activity. The alkylcarbamates of the N-phenylacridin-9-amine\r\nis more effective than their corresponding parent N-phenylacridin-9-amine derivatives. The cytotoxic activity of the Nphenylacridin-\r\n9-amine ethylcarbamates is decreased with increasing length and size of the alkyl function. It is also having drug-\r\nDNA binding affinity which affects the antitumor activity of 9-anilinoacridines. These compound having higher cytotoxic activity\r\ndue to high lipophilicity. We used 25 compounds and their pIC50 activities on the HT-29 cell line for the 2-D QSAR study. Here the\r\n2D-QSAR studies of N-phenylacridin-9-amine analogues were performed by using software chem-draw ultra-8.0, openbable-\r\n2.2.1, dragon, valstat. We are considering here two model equations for QSAR study. The value of linearity r2 for model-1 of HT-\r\n29 cell line (model-1) is; r2 = 0.922608, Q2 = 0.888065, Spress = 0.232872 and SDEP = 0.21343 while this value for model-2 of\r\nHT-29 cell line is; r2 = 0.879102, Q2 = 0.835641, Spress = 0.282183 and SDEP = 0.258625. Both models were validated by the\r\nvalstat software.
Loading....